

# Anne Sophie Kubasch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2752708/publications.pdf>

Version: 2024-02-01

39  
papers

979  
citations

623734

14  
h-index

454955

30  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1491  
citing authors

#	ARTICLE	IF	CITATIONS
1	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 1668-1679.	10.7	250
2	Randomized controlled trials &ndash; a matter of design. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 1341.	2.2	159
3	Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1 $\beta$ expression and release. <i>Clinical Immunology</i> , 2015, 161, 300-307.	3.2	88
4	Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO). <i>Rheumatology International</i> , 2016, 36, 769-779.	3.0	61
5	CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. <i>Blood</i> , 2021, 138, 1727-1732.	1.4	58
6	Current challenges and unmet medical needs in myelodysplastic syndromes. <i>Leukemia</i> , 2021, 35, 2182-2198.	7.2	46
7	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	2.4	41
8	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. <i>Leukemia</i> , 2020, 34, 1182-1186.	7.2	39
9	Development of luspatercept to treat ineffective erythropoiesis. <i>Blood Advances</i> , 2021, 5, 1565-1575.	5.2	39
10	Laser Doppler Assessment of Vasomotor Axon Reflex Responsiveness to Evaluate Neurovascular Function. <i>Frontiers in Neurology</i> , 2017, 8, 370.	2.4	26
11	Iron overload and its impact on outcome of patients with hematological diseases. <i>Molecular Aspects of Medicine</i> , 2020, 75, 100868.	6.4	25
12	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2924-2943.	9.4	20
13	Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3853.	4.1	18
14	Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML. <i>Cancers</i> , 2018, 10, 158.	3.7	15
15	Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial. <i>Blood</i> , 2018, 132, 4045-4045.	1.4	15
16	Cutaneous Autonomic Pilocomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease (CAPTURE PD): Protocol for a Multicenter Study. <i>Frontiers in Neurology</i> , 2017, 8, 212.	2.4	14
17	Targeting health-related quality of life in patients with myelodysplastic syndromes &quot; Current knowledge and lessons to be learned. <i>Blood Reviews</i> , 2021, 50, 100851.	5.7	14
18	Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 1187-1190.	5.2	8

#	ARTICLE	IF	CITATIONS
19	Patient stratification in myelodysplastic syndromes: how a puzzle may become a map. Hematology American Society of Hematology Education Program, 2020, 2020, 418-425.	2.5	6
20	Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma. Frontiers in Oncology, 2020, 10, 219.	2.8	6
21	Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape. Neoplasia, 2021, 23, 1101-1109.	5.3	6
22	Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany. Annals of Hematology, 2020, 99, 2085-2093.	1.8	4
23	Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents. Blood, 2020, 136, 37-38.	1.4	4
24	The wolf of hypomethylating agent failure: what comes next?. Haematologica, 2019, 104, 1505-1508.	3.5	3
25	Predicting Early Relapse for Patients with Multiple Myeloma through Machine Learning. Blood, 2021, 138, 2953-2953.	1.4	3
26	Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. American Journal of Hematology, 2021, 96, E207-E210.	4.1	2
27	Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial. Blood, 2019, 134, 644-644.	1.4	2
28	Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series. Frontiers in Oncology, 2022, 12, 866470.	2.8	2
29	The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q. Blood, 2018, 132, 4360-4360.	1.4	1
30	Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution. Blood, 2021, 138, 3278-3278.	1.4	1
31	Facing the challenge: Novel treatment options for patients with myelodysplastic syndromes. HemaSphere, 2018, 2, 135-137.	2.7	1
32	Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?. JAMA Oncology, 2020, 6, 493.	7.1	0
33	Aicardi-Goutières Syndrome (AGS) (AGS7). , 2019, , 1-5.		0
34	Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network. Blood, 2019, 134, 2998-2998.	1.4	0
35	Myelodysplastische Syndrome (MDS). , 2020, , 403-417.		0
36	Aicardi-Goutières Syndrome (AGS) (AGS7). , 2020, , 9-13.		0

#	ARTICLE	IF	CITATIONS
37	Hematopoietic Cell Transplantation for MDS Patients. , 2020, , 165-173.		0
38	GynÄkologische Tumoren. , 2020, , 863-898.		0
39	A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia. Blood, 2020, 136, 44-45.	1.4	0